Rheumatoid arthritis and cell therapy

Category: Conditions & evidence · Editorial Review: Updated 20 October 2026 · 3 minute read

The immune process matters

Rheumatoid arthritis is an inflammatory autoimmune disease that can damage joints and affect other parts of the body. This differs from wear-related osteoarthritis. A local injection marketed to rebuild cartilage does not automatically treat the systemic disease. A rheumatologist should assess disease activity and the adequacy of established treatment before an experimental cell option is considered.

Research does not equal routine care

Scientists study immune cells and stromal cells to understand inflammation and repair. That research can lead to new targets or future interventions without establishing that a commercial stem cell product is effective. Ask whether the claimed benefit comes from laboratory work, an uncontrolled patient series or a comparative clinical trial of the actual treatment being offered.

Protect ongoing treatment

Do not discontinue prescribed disease-modifying therapy because a provider describes an infusion as an immune reset. Ask your rheumatologist to assess any proposed change and the risk of a flare. The clinician recommending cell treatment should explain interactions with current medicines and how infection risk will be addressed.

What to measure

Useful outcomes include disease activity, function, pain, medication requirements and prevention of joint damage. Ask which measures the center records and how long it follows patients. Bring blood results, imaging and a complete medication history, including prior failures or adverse effects. A coordinated plan is more valuable than an isolated procedure report.

Continue exploring

• Acute myeloid leukemia and transplantation
• Acute lymphoblastic leukemia and transplantation
• Multiple myeloma and autologous transplant
• Prepare your consultation checklist

Sources & further reading

• Primary patient information and research

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.